CONTEXT: Transcript of a virtual ASCO presentation on an RWE study in specific prostate cancer group | Available as a 7 minute video log for those who would rather listen than read
IMPACT: Low
READ TIME: 1 min
Quality Level Mean [1 – 10]: 7
1. “Stephen Freedland, MD, Cedar-Sinai Medical Center, Los Angeles, CA, and Durham VA Medical Center, NC, discusses study results exploring real-world evidence on survival outcomes among men with castrattion-resistant prostate cancer who initiated androgen deprivation therapy (ADT) or ADT combined with anti-androgens, docetaxel, or abiraterone.”
2. “We wanted to understand how that practice pattern has changed over time, as well as to see if there are any differences in progression and survival rates between men on ADT versus those on ADT plus anti‑androgens.”
3. “If we look down, in terms of some of the key findings that we saw in the study, was first off that, if we went back to an era before CHAARTED, before we knew docetaxel and the AR‑targeted therapies had a benefit, you saw that about 97% of the men were getting either ADT alone, which was two-thirds of men, or ADT plus anti‑androgens.”
4. “What’s been a little disappointing, I would say—but I think represents real‑world practice, and we’ve seen this outside the VA—is that, even as we moved onto 2017 to early 2018, where we now had CHAARTED, you had LATITUDE, you had the STAMPEDE, you had multiple studies suggesting the benefits, you still saw 60% of the men were getting ADT alone.”
5. “Freedland SJ, Sandin R, Sah J. Survival outcomes in patients with metastatic castration-sensitive prostate cancer (mCSPC): A real-world evidence study.”